Regeneron director sells 400 shares at $850
REGENERON PHARMACEUTICALS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
REGENERON PHARMACEUTICALS, INC. (REGN) director Kathryn Guarini reported option-related transactions in the company’s stock. On September 2, 2026, she exercised options for 400 shares at an exercise price of $719.37 per share and sold 400 shares at $850.00 per share, under a Rule 10b5-1(c) trading plan adopted on February 13, 2026. Following the option exercise, she continued to hold options covering 1,158 shares of common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 400 shares ($52K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Guarini Kathryn
Role
Director
Sold
400 shs ($340K)
Approx. gross sale proceeds
$340K
Approx. exercise cost
$288K
Approx. pre-tax spread
$52K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) F1, F2 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 400 | $719.37 | $288K |
| Sale | Common Stock F1 | 400 | $850.00 | $340K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 1,158 contracts (Direct);
Common Stock — 603 shares (Direct)
Footnotes (2)
- F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
- F2. On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
Key Figures
Options exercised: 400 shares
Exercise price: $719.37 per share
Shares sold: 400 shares
+4 more
7 metrics
Options exercised
400 shares
Non-qualified stock options exercised on September 2, 2026
Exercise price
$719.37 per share
Exercise price for 400 options exercised on September 2, 2026
Shares sold
400 shares
Common shares sold on September 2, 2026 after option exercise
Sale price
$850.00 per share
Reported sale price for 400 common shares on September 2, 2026
Options held after transaction
1,158 shares
Options remaining following the reported option exercise
Option expiration date
January 2, 2035
Expiration date of the non-qualified stock options exercised
10b5-1 plan adoption date
February 13, 2026
Date the Rule 10b5-1(c) trading plan governing the transactions was adopted
Key Terms
Non-Qualified Stock Option, Rule 10b5-1(c), annual meeting of shareholders
3 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1(c) regulatory
"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did REGN director Kathryn Guarini report on this Form 4?
She reported exercising options for 400 shares of Regeneron common stock at an exercise price of $719.37 per share and selling 400 shares at $850.00 per share on September 2, 2026, all under a pre-arranged Rule 10b5-1(c) trading plan.
Was the September 2, 2026 REGN trade by Kathryn Guarini under a Rule 10b5-1 plan?
Yes. The disposition and acquisition were made pursuant to a plan intended to comply with Rule 10b5-1(c), which was adopted on February 13, 2026, and the filing affirms use of a Rule 10b5-1 trading plan.
What options did Kathryn Guarini exercise in REGN on September 2, 2026?
She exercised non-qualified stock options covering 400 shares of Regeneron common stock at an exercise price of $719.37 per share, from an option grant expiring on January 2, 2035.
How many Regeneron options does Kathryn Guarini hold after the reported transactions?
After exercising part of her award, she continued to hold options covering 1,158 shares of Regeneron common stock, as reported in the filing’s post-transaction holdings information for the option award.
What does the Form 4 say about vesting of Kathryn Guarini’s Regeneron stock options?
It states that on the date of the company’s first annual meeting of shareholders following the date of grant, a portion of the options became exercisable based on the portion of one year that had passed, and the remainder became exercisable on the first anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
